z-logo
Premium
Efficacy of a new mouth rinse formulation based on 0.07% cetylpyridinium chloride in the control of plaque and gingivitis: a 6‐month randomized clinical trial
Author(s) -
Costa Xavier,
Laguna Estefanía,
Herrera David,
Serrano Jorge,
Alonso Bettina,
Sanz Mariano
Publication year - 2013
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/jcpe.12158
Subject(s) - cetylpyridinium chloride , placebo , gingivitis , medicine , dentistry , gingival inflammation , randomized controlled trial , placebo group , clinical trial , mouth rinse , pulmonary surfactant , pathology , physics , alternative medicine , thermodynamics
Aim To assess the efficacy of a 0.07% cetylpyridinium chloride ( CPC ) mouth rinse in the control of plaque and gingival inflammation during a 6‐month period. Material and Methods Adult subjects with moderate gingivitis were selected [≥40% bleeding on marginal probing ( BOMP )]. After retrieving microbiological samples and evaluating the clinical parameters (plaque, BOMP and stain indexes), a professional prophylaxis was performed and subjects were randomly assigned to the test ( CPC mouth rinse) or to the placebo group. Subjects were re‐assessed after 3 and 6 months. Results A total of 67 patients (35 test, 32 placebo) were included in the analysis. At 6 months, intra‐group significant plaque reductions were observed in the test group (0.691, p  < 0.001), but not in the placebo (0.181, p  = 0.653). At 6 months, the mean BOMP values were lower in the test group ( p  = 0.052). Changes between baseline and 6 months were significantly higher in the test group both for plaque ( p  = 0.002) and BOMP ( p  = 0.037) when compared with the placebo. A microbiological impact was observed in the test group, especially for Prevotella intermedia . Conclusion The evaluated 0.07% CPC ‐based mouth rinse, used three times per day adjunctively to mechanical tooth cleaning, prevents plaque accumulation and gingival inflammation, as compared to the placebo, for at least 6 months.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom